Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

Rhea-AI Summary

Metacrine, Inc. (Nasdaq: MTCR) announced that its CEO, Preston Klassen, will present at the H.C. Wainwright 2021 Global Life Sciences Conference on March 9-10, 2021. The presentation will be accessible for on-demand viewing starting March 9 at 7:00 a.m. ET, with an archived version available on Metacrine's website for 60 days. Metacrine focuses on developing therapies for liver and gastrointestinal diseases, with two candidates, MET409 and MET642, in clinical trials for non-alcoholic steatohepatitis (NASH).

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the H.C. Wainwright 2021 Global Life Sciences Conference, being held March 9-10, 2021.

The presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00 a.m. ET, and will also be available in the investor section of the company's website at www.metacrine.com. The webcast will be archived for 60 days following the presentation.

About Metacrine
Metacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in clinical trials. The company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH). MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being advanced into a 16-week monotherapy trial in patients with NASH.

Contact:
Chelcie Lister
THRUST Strategic Communications
910.777.3049
investors@metacrine.com

FAQ

When will Metacrine present at the H.C. Wainwright 2021 Global Life Sciences Conference?

Metacrine will present on March 9-10, 2021.

How can I view Metacrine's presentation?

The presentation will be available on-demand starting March 9, 2021, at 7:00 a.m. ET and can be accessed on Metacrine's website.

What diseases is Metacrine focused on treating?

Metacrine is focused on developing therapies for liver and gastrointestinal diseases.

What are the clinical trials focused on at Metacrine?

Metacrine's clinical trials are currently investigating MET409 and MET642 as potential treatments for non-alcoholic steatohepatitis (NASH).

What is the status of MET409's clinical trials?

MET409 has completed a 12-week monotherapy trial and is undergoing a combination trial with empagliflozin in NASH and type 2 diabetes patients.

What is the status of MET642's clinical trials?

MET642 has completed a 14-day Phase 1 trial and is moving into a 16-week monotherapy trial for NASH.